Last edition
News about "Otarmeni gene therapy"
US FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss
US Food and Drug Administration (FDA) approves Regeneron’s Otarmeni, the first AAV-based gene therapy, offering a potential treatment for severe-to-profound hearing loss.
Otarmeni Gene Therapy | 27/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members